-
公开(公告)号：US20150166636A1
公开(公告)日：2015-06-18
申请号：US14406232
申请日：2013-06-14
发明人： Tomoyuki Igawa , Naoka Hironiwa , Shojiro Kadono , Atsushi Matsuo , Taichi Kuramochi , Futa Mimoto
IPC分类号： C07K16/00
CPC分类号： C07K16/00 , C07K16/22 , C07K16/2848 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/94 , C07K2319/30
摘要： The present inventors have successfully prepared an antibody Fc region dimer that has binding activity against each of an antigen and FcγR, but does not bind to the antigen and the FcγR at the same time, and a polypeptide comprising the Fc region dimer. The present invention enables the preparation of a multispecific binding polypeptide capable of avoiding an adverse reaction that may be caused by its binding to an antigen and FcγR at the same time. Thus, the present invention provides a polypeptide suitable as a drug.
摘要翻译： 本发明人成功地制备了对抗原和FcγR各自具有结合活性但不同时与抗原和FcγR结合的抗体Fc区二聚体和包含Fc区二聚体的多肽。 本发明能够制备能够避免可能由其与抗原和FcγR结合同时引起的不良反应的多特异性结合多肽。 因此，本发明提供了适合作为药物的多肽。
-
公开(公告)号：US11912989B2
公开(公告)日：2024-02-27
申请号：US17182331
申请日：2021-02-23
发明人： Tomoyuki Igawa , Shigero Tamba , Shun Shimizu , Kanako Tatsumi , Shojiro Kadono , Hiroki Kawauchi , Kazuhiro Ohara , Masayuki Matsushita , Takashi Emura , Masaki Kamimura
IPC分类号： C40B40/10 , C12N15/10 , C07K16/28 , C07K16/24 , C07K16/00 , C07K16/42 , C07K16/44 , C40B50/06 , C07K16/30
CPC分类号： C12N15/1093 , C07K16/00 , C07K16/005 , C07K16/248 , C07K16/2809 , C07K16/2863 , C07K16/2866 , C07K16/30 , C07K16/4283 , C07K16/44 , C40B50/06 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/92
摘要： An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries. Various diseases originating from target tissues can be treated in a target tissue-specific manner by using the antigen-binding molecules of the present invention.
-
公开(公告)号：US20240026000A1
公开(公告)日：2024-01-25
申请号：US18345750
申请日：2023-06-30
发明人： Tomoyuki Igawa , Shojiro Kadono , Naoka Hironiwa , Mika Sakurai
CPC分类号： C07K16/2809 , C07K16/2866 , C07K16/2875 , C07K16/4283 , C07K16/30 , C07K16/2863 , C07K16/2848 , C07K16/2896 , C07K2317/24 , C07K2317/31 , C07K2317/526 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2319/00 , C07K2319/70
摘要： The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.
-
公开(公告)号：US20230279099A1
公开(公告)日：2023-09-07
申请号：US18138888
申请日：2023-04-25
发明人： Tomoyuki Igawa , Shigero Tamba , Kanako Tatsumi , Shun Shimizu , Shojiro Kadono
IPC分类号： C07K16/24 , G01N33/68 , C07K16/44 , C07K16/30 , C07K16/18 , C07K16/28 , C07K16/00 , A61K39/00
CPC分类号： C07K16/248 , G01N33/6845 , C07K16/44 , C07K16/30 , C07K16/18 , C07K16/2866 , C07K16/00 , G01N33/6869 , C07K16/005 , C07K2317/92 , C07K2317/34 , C07K2317/732 , C07K2317/55 , G01N2500/20 , G01N2500/00 , A61K2039/505 , C07K2317/21 , G01N2333/5412
摘要： The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.
-
公开(公告)号：US20230140797A1
公开(公告)日：2023-05-04
申请号：US17854023
申请日：2022-06-30
发明人： Tomoyuki Igawa , Atsuhiko Maeda , Yuki Iwayanagi , Kenta Haraya , Hitoshi Katada , Shojiro Kadono , Futa Mimoto
摘要： The present invention provides antigen-binding molecules containing (i) an antigen-binding domain whose antigen-binding activity varies depending on ion concentration conditions, (ii) an FcγR-binding domain having Fcγ RIIb-selective binding activity, and (iii) an FcRn-binding domain having FcRn-binding activity under an acidic pH range condition, and methods of decreasing plasma antigen concentration as compared to before administering the molecule, which include the step of administering the molecule.
-
公开(公告)号：US20210261648A1
公开(公告)日：2021-08-26
申请号：US17028210
申请日：2020-09-22
发明人： Hitoshi Katada , Shojiro Kadono , Futa Mimoto , Tomoyuki Igawa
摘要： An objective of the present invention is to provide an Fc region variant with enhanced FcγRIIb-binding activity, and/or enhanced binding selectivity to FcγRIIb compared to FcγRIIa (type R), as compared to those of a polypeptide containing an Fc region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing FcγRIIb-binding activity and also enhancing binding selectivity to FcγRIIb compared to FcγRIIa (type R).
It was found that a polypeptide containing an antibody Fc region variant that contains an amino acid sequence in which an amino-acid alteration at position 238 (EU numbering) is combined with other specific amino-acid alterations enhances FcγRIIb-binding activity, and/or enhances binding selectivity to FcγRIIb compared to FcγRIIa (type R).-
公开(公告)号：US20210180049A1
公开(公告)日：2021-06-17
申请号：US17182331
申请日：2021-02-23
发明人： Tomoyuki Igawa , Shigero Tamba , Shun Shimizu , Kanako Tatsumi , Shojiro Kadono , Hiroki Kawauchi , Kazuhiro Ohara , Masayuki Matsushita , Takashi Emura , Masaki Kamimura
IPC分类号： C12N15/10 , C07K16/28 , C07K16/24 , C07K16/00 , C07K16/42 , C07K16/44 , C40B50/06 , C07K16/30
摘要： An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries. Various diseases originating from target tissues can be treated in a target tissue-specific manner by using the antigen-binding molecules of the present invention.
-
公开(公告)号：US20180057607A1
公开(公告)日：2018-03-01
申请号：US15562186
申请日：2016-03-31
发明人： Tomoyuki Igawa , Hitoshi Katada , Yuji Hori , Shojiro Kadono
CPC分类号： C07K16/464 , C07K16/00 , C07K16/2866 , C07K16/468 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/624 , G01N33/15 , G01N33/50 , G01N33/53
摘要： It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating homo variants of plural types of heavy chain constant region-containing polypeptides differing in antigen-binding activity under a reducing condition that reorganize the inter-polypeptide disulfide bond between cysteine residues outside of core hinge regions. A feature of the production method of the present invention is that amino acid residues in the core hinge regions do not form any disulfide bond.
-
公开(公告)号：US20150166654A1
公开(公告)日：2015-06-18
申请号：US14402574
申请日：2013-05-30
发明人： Tomoyuki Igawa , Shigero Tamba , Kanako Tatsumi , Shun Shimizu , Shojiro Kadono
CPC分类号： C07K16/248 , A61K2039/505 , C07K16/00 , C07K16/005 , C07K16/18 , C07K16/2866 , C07K16/30 , C07K16/44 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/732 , C07K2317/92 , G01N33/6845 , G01N33/6869 , G01N2333/5412 , G01N2500/00 , G01N2500/20
摘要： The present inventors discovered that the above-mentioned problems can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.
摘要翻译： 本发明人发现上述问题可以通过产生含抗原结合结构域的抗原结合分子来解决，其抗原结合活性随目标组织特异性化合物的浓度而变化。 本发明的抗原结合分子的使用使得能够以对靶组织特异性的方式来源于待治疗的靶组织的各种疾病。
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.033 秒)
